Bacteremia Clinical Trial
Official title:
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness- BALANCE on the Wards: A Pilot RCT
The burden of bloodstream infections is large and increasing over time. Antibiotic overuse continues to drive increased rates of antimicrobial-resistant pathogens across Canada. However, prospective audits have revealed that 30-50% of antibiotic utilization is unnecessary or inappropriate. If shorter duration therapy is as effective as longer duration therapy for these infections, antimicrobial consumption would be decreased. A pilot trial (approved by the Sunnybrook Research Ethics Board), is underway in critically ill patients at 17 Canadian ICUs. Investigators have successfully demonstrated feasibility with respect to protocol adherence and recruitment rates in the ICU. Investigators now aim to conduct a similar pilot RCT among non-ICU patients admitted to hospital wards with bloodstream infections to determine feasibility and protocol adherence of the same trial protocol.
Bloodstream infections are a common and serious problem, and are associated with increased
morbidity and mortality. At the same time, antibiotic overuse is also a common and serious
problem, in that 30-50% of antibiotic use is unnecessary or inappropriate, and results in
avoidable drug side effects such as kidney failure, Clostridium difficile infection,
increased costs, and spiraling antibiotic resistance rates. The greatest contributor to
antibiotic overuse is excessive durations of treatment.
Extensive research has demonstrated that shorter duration antibiotic treatment (less or equal
to 7 days) is as effective as longer duration treatment for a variety of infectious diseases,
but this question has not been directly studied in the setting of bloodstream infection. Our
team's systematic review of the medical literature, national survey of Canadian infectious
diseases and critical care physicians, and multicentre retrospective study all support the
need for a randomized controlled trial comparing shorter (7 days) versus longer (14 days)
antibiotic therapy for bloodstream infections.
Prior to performing the main trial, our pilot RCT in critically ill patients is
near-completion.
In order to increase the generalizability to non-critically ill patients, Investigators want
to conduct a similar pilot RCT in non-critically ill patients (BALANCE on the Wards) to
establish the feasibility of the research design, and to optimize the definitive trial.
Investigators will conduct a randomized concealed allocation trial of shorter duration (7
days) versus longer duration (14 days) antibiotic treatment for patients with bloodstream
infections across all non-ICU hospital wards in Sunnybrook Hospital (BALANCE on the Wards).
Our ongoing BALANCE pilot RCT in ICU is approved by the Sunnybrook REB (PIN: 187-2014). The
BALANCE on Wards pilot trial will use the same protocol, informed consent form and the case
report forms that are approved by the Sunnybrook REB with minimal changes to make it ward
specific. If the investigators are able to achieve the primary outcome of this trial in
Sunnybrook hospital, the main BALANCE trial will potentially involve enrolment of non-ICU
patients at all (or a subset of) participating sites.
If eligibility criteria and study procedures are substantially unchanged, results of the both
the pilot BALANCE RCTs will be rolled into the dataset for the main BALANCE RCT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |